Compare · AFIB vs MDT
AFIB vs MDT
Side-by-side comparison of Acutus Medical Inc. (AFIB) and Medtronic plc. (MDT): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AFIB and MDT operate in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), so they compete in similar markets.
- MDT is the larger of the two at $106.50B, about 1914.6x AFIB ($55.6M).
- MDT has hit the wire 2 times in the past 4 weeks while AFIB has been quiet.
- MDT has more recent analyst coverage (25 ratings vs 7 for AFIB).
- Company
- Acutus Medical Inc.
- Medtronic plc.
- Price
- $0.09-28.15%
- $83.19-0.41%
- Market cap
- $55.6M
- $106.50B
- 1M return
- -
- +2.28%
- 1Y return
- -
- -7.27%
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- NASDAQ
- NYSE
- IPO
- 2020
- News (4w)
- 0
- 2
- Recent ratings
- 7
- 25
Acutus Medical Inc.
Acutus Medical, Inc., an arrhythmia management company, designs, manufactures, and markets a range of tools for catheter-based ablation procedures to treat various arrhythmias in the United States and internationally. Its product portfolio includes novel access sheaths, transseptal crossing tools, diagnostic and mapping catheters, conventional and contact force ablation catheters, and mapping and imaging consoles and accessories, as well as supporting algorithms and software programs. Acutus Medical, Inc. was incorporated in 2011 and is based in Carlsbad, California.
Medtronic plc.
Medtronic plc develops, manufactures, distributes, and sells device-based medical therapies to hospitals, physicians, clinicians, and patients worldwide. It operates through four segments: Cardiovascular Portfolio, Neuroscience Portfolio, Medical Surgical Portfolio, and Diabetes Operating Unit. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; AF ablation products; insertable cardiac monitor systems; mechanical circulatory support; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves; percutaneous coronary intervention stents, surgical valve replacement and repair products, endovascular stent grafts, percutaneous angioplasty balloons, and products to treat superficial venous diseases in the lower extremities. The Medical Surgical Portfolio segment offers surgical products, including surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, surgical artificial intelligence and robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology and lung products, and various therapies to treat diseases. The Neuroscience Portfolio segment offers products for spinal surgeons; neurosurgeons; neurologists; pain management specialists; anesthesiologists; orthopedic surgeons; urologists; urogynecologists; interventional radiologists; ear, nose, and throat specialists; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems and robotic guidance systems used in robot assisted spine procedures; and therapies for vasculature in and around the brain. The Diabetes Operating Unit segment offers insulin pumps and consumables, and continuous glucose monitoring systems. The company was founded in 1949 and is headquartered in Dublin, Ireland.
Latest AFIB
- SEC Form 10-K filed by Acutus Medical Inc.
- Acutus Medical Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Acutus Medical Reports Full Year 2024 Financial Results
- SEC Form 4 filed by Director by deputization Flynn James E
- Amendment: SEC Form SCHEDULE 13D/A filed by Acutus Medical Inc.
- SEC Form 15-15D filed by Acutus Medical Inc.
- SEC Form EFFECT filed by Acutus Medical Inc.
- SEC Form EFFECT filed by Acutus Medical Inc.
- Amendment: SEC Form SCHEDULE 13D/A filed by Acutus Medical Inc.
- SEC Form S-8 POS filed by Acutus Medical Inc.
Latest MDT
- Medtronic completes acquisition of SPR, expanding patient access to minimally invasive, non-opioid treatment of chronic and acute pain
- SVP, Chief HR Officer Walter Matthew R. sold $257,931 worth of Ordinary Shares (3,102 units at $83.15), decreasing direct ownership by 8% to 35,694 units (SEC Form 4)
- New insider Thompson Kweli claimed ownership of 30,018 units of Ordinary Shares (SEC Form 3)
- SEC Form IRANNOTICE filed by Medtronic plc.
- SEC Form 10-K filed by Medtronic plc.
- Medtronic completes acquisition of Scientia Vascular, seamlessly integrating access and therapeutic portfolios for neurovascular care
- EVP & President Cardiovascular Kiil Harry Skip sold $336,965 worth of Ordinary Shares (4,189 units at $80.44), decreasing direct ownership by 10% to 37,227 units (SEC Form 4)
- EVP & President Cardiovascular Kiil Harry Skip covered exercise/tax liability with 6,817 units of Ordinary Shares, decreasing direct ownership by 14% to 41,416 units (SEC Form 4)
- Chairman and CEO Martha Geoffrey covered exercise/tax liability with 41,936 units of Ordinary Shares, decreasing direct ownership by 12% to 301,163 units (SEC Form 4)
- EVP, Pres MedSurg and Americas Marinaro Michael covered exercise/tax liability with 7,471 units of Ordinary Shares, decreasing direct ownership by 11% to 63,122 units (SEC Form 4)